These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3279997)

  • 1. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.
    Belch A; Shelley W; Bergsagel D; Wilson K; Klimo P; White D; Willan A
    Br J Cancer; 1988 Jan; 57(1):94-9. PubMed ID: 3279997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
    J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study.
    Pavlovsky S; Corrado C; Santarelli MT; Saslavsky J; Cavagnaro F; Palau M; de Tezanos Pinto M; Huberman A; Lein JM
    J Clin Oncol; 1988 May; 6(5):769-75. PubMed ID: 3284974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of multiple myeloma: a randomized study of three different regimens.
    Tribalto M; Amadori S; Cantonetti M; Franchi A; Papa G; Pileri A; Boccadoro M; Dammacco F; Vacca A; Centurioni R
    Leuk Res; 1985; 9(8):1043-9. PubMed ID: 3900591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
    Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA;
    N Engl J Med; 2012 May; 366(19):1759-69. PubMed ID: 22571200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
    J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
    Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
    J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
    Beksac M; Haznedar R; Firatli-Tuglular T; Ozdogu H; Aydogdu I; Konuk N; Sucak G; Kaygusuz I; Karakus S; Kaya E; Ali R; Gulbas Z; Ozet G; Goker H; Undar L
    Eur J Haematol; 2011 Jan; 86(1):16-22. PubMed ID: 20942865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden.
    Osterborg A; Björkholm M; Björeman M; Brenning G; Carlson K; Celsing F; Gahrton G; Grimfors G; Gyllenhammar H; Hast R
    Blood; 1993 Mar; 81(6):1428-34. PubMed ID: 8453092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden.
    Ahre A; Björkholm M; Mellstedt H; Brenning G; Engstedt L; Gahrton G; Gyllenhammar H; Holm G; Johansson B; Järnmark M
    Cancer Treat Rep; 1984 Nov; 68(11):1331-8. PubMed ID: 6388832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma.
    Montuoro A; De Rosa L; De Blasio A; Pacilli L; Petti N; De Laurenzi A
    Br J Haematol; 1990 Nov; 76(3):365-8. PubMed ID: 2261347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
    Pavlovsky S; Saslavsky J; Tezanos Pinto M; Palmer L; Curuchet M; Lein JM; Garay G; Dragosky M; Quiroga-Micheo E; Huberman AB
    J Clin Oncol; 1984 Jul; 2(7):836-40. PubMed ID: 6376722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).
    Pönisch W; Mitrou PS; Merkle K; Herold M; Assmann M; Wilhelm G; Dachselt K; Richter P; Schirmer V; Schulze A; Subert R; Harksel B; Grobe N; Stelzer E; Schulze M; Bittrich A; Freund M; Pasold R; Friedrich T; Helbig W; Niederwieser D;
    J Cancer Res Clin Oncol; 2006 Apr; 132(4):205-12. PubMed ID: 16402269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.
    Sacchi S; Marcheselli R; Lazzaro A; Morabito F; Fragasso A; Di Renzo N; Balleari E; Neri S; Quarta G; Ferrara R; Vigliotti ML; Polimeno G; Musto P; Consoli U; Zoboli A; Buda G; Pastorini A; Masini L
    Leuk Lymphoma; 2011 Oct; 52(10):1942-8. PubMed ID: 21663513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients.
    Lund J; Uttervall K; Liwing J; Gahrton G; Alici E; Aschan J; Holmberg E; Nahi H
    Eur J Haematol; 2014 Jan; 92(1):19-25. PubMed ID: 24118547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.